Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Enteric Hyperoxaluria Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Kidney Axis in Enteric Hyperoxaluria

NCT05124886
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
Moderately High Oxalate (MOx) Diet
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

NCT02503345
View directory record Official record
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
Interventions
ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

NCT03456830
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
ALLN-177, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 23, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Prospective Research Rare Kidney Stones (ProRKS)

NCT02780297
View directory record Official record
Conditions
Hyperoxaluria, Cystinuria, Dent Disease, Lowe Syndrome, Adenine Phosphoribosyltransferase Deficiency
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 5:10 AM EDT
Terminated Phase 3 Interventional

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

NCT03847090
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
Reloxaliase, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
64
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxazyme in Patients With Hyperoxaluria

NCT01127087
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Oxazyme
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

NCT03095885
View directory record Official record
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
Interventions
Test Meal
Other
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Tucson, Arizona • Little Rock, Arkansas • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT04629170
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
SYNB8802, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria

NCT00588120
View directory record Official record
Conditions
Enteric Hyperoxaluria, Hyperoxaluria
Interventions
C-13 labeled oxalate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Early Phase 1 Interventional

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

NCT05377112
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
SYNB8802v1, Placebo
Drug · Other
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

NCT03391804
View directory record Official record
Conditions
Enteric Hyperoxaluria, Primary Hyperoxaluria, Hyperoxalemia
Interventions
ALLN-177
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 23, 2026, 5:10 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
FB-001, Placebo
Biological
Lead sponsor
Federation Bio Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

NCT02547805
View directory record Official record
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones, Dietary Hyperoxaluria
Interventions
ALLN-177, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Pheonix, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 23, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

NCT02289755
View directory record Official record
Conditions
Hyperoxaluria, Nephrolithiasis
Interventions
ALLN-177
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Indianapolis, Indiana • Lake Success, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 23, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 23, 2026, 5:10 AM EDT